FBI NGI November 2019 Fact Sheet Statistics:

• The FBI Next Generation Identification (NGI) database contains the fingerprints of over 145.9 million individuals (both civil and criminal).
• Over 97.5% of the Tenprint Rapsheet Request (TPRS) responses were completed within 19 seconds.

Fiscal Year 2019 Average

In Touch 

with

 Your World

FREEDOM TO TRAVEL ABROAD

For the Pharma Technology Industry

FBI fingerprint-based background checks are increasingly required for U.S. Citizens to live, work and travel overseas in many countries such as China, South Korea, Australia, South Africa, Spain and Israel.

Accurate Biometrics was the first authorized FBI Channeler, to provide access to FBI Identity History Summary Checks (IdHS), or Departmental Orders (556-73). For 20 years we have been a leader in the fingerprint industry with our technology capabilities, expertise and dedicated service to government agencies and private industries.

Our expertise will assist your company:

  • National U.S. Collection Network, over 800 locations in 50 states
  • Fast access to Identity History Summary Checks for Visa  requirements direct from the FBI CJIS, several delivery options are available including a secure watermarked hard copy of the results
  • SAME DAY International fingerprint card processing
  • Certified AWS GOV Cloud Hosting Environment for FBI Channeling

For more information, contact...

Will Peterson 
Director of Business Development
708-887-9258
wpeterson@accuratebiometrics.com
AccurateBiometrics.com

Go to article: Home | An (in)active pill problemGo to article: EditorialGo to article: SHL Group Company InsightGo to article: Scandinavian HealthGo to article: ContentsGo to article: NSFGo to article: NewsGo to article: AlmacGo to article: Covid-19 executive briefing by GlobalDataGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Digital biomarkers are emerging as important predictive tools to support the gloGo to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: Almost 70 potential Covid-19 drug and experimental compound candidates identifiedGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: Risk assessment of Covid-19 on patients suffering from IBDGo to article: Zenatek Go to article: The pharma industry briefingGo to article: FargoGo to article: Another bump in the road for mumps treatmentGo to article: Last TechnologyGo to article: From Covid-19 to SARS: what becomes of the whistleblowers?Go to article: ButterworthGo to article: Peptomyc: the quest for a ‘universal’ cancer treatmentGo to article: Q&A: is pharma ready to address the health effects of climate change?Go to article: Modality SolutionsGo to article: Not-so-inactive ingredients: a sore spot for patients?Go to article: Beyond M&As: will 2020 be the year of the spin-off? Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Q&A with Genocea: improving cancer treatment with precise, personalised targetsGo to article: MimotopesGo to article: Pharma Playbook: an inside look at Signals Analytics vast therapeutic database Go to article: ILC Dover Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue